Voltage-Gated Ion Channels as Drug Targets
Methods and Principles in Medicinal Chemistry (Band Nr. 29)
1. Auflage Februar 2006
XII, 480 Seiten, Hardcover
121 Abbildungen
48 Tabellen
Monographie
Wiley Online LibraryInhaltProbekapitelIndexListe der Autoren
Kurzbeschreibung
Edited by prominent researchers in the field, this is a unique resource for drug developers and physiologists seeking a molecular-level understanding of ion channel pharmacology.
Jetzt kaufen
Preis: 245,00 €
Preis inkl. MwSt, zzgl. Versand
Euro-Preise für Wiley-VCH- und Ernst & Sohn-Titel sind nur für Deutschland gültig. In EU-Ländern gilt die lokale Mehrwertsteuer. Portokosten werden berechnet.
- Gedruckte Ausgabe vergriffen -
Edited by the most prominent person in the field and top researchers at US pharmaceutical companies, this is a unique resource for drug developers and physiologists seeking a molecular-level understanding of ion channel pharmacology.
After an introduction to the topic, the authors evaluate the structure and function of ion channels, as well as related drug interaction. A section on assay technologies is followed by a section each on calcium, sodium and potassium channels. Further chapters cover genetic and acquired channelopathies, before the book closes with a look at safety issues in ion channel drug development.
For medicinal and pharmaceutical chemists, biochemists, molecular biologists and those working in the pharmaceutical industry.
Structure and Function of Ion Channels
Drug Interaction at Ion Channels
Assay Technologies
Binding Studies
Ion Fluxes
Fluorescence Studies
Patch Clamping
Calcium Channels
Overview
T-type Channels
L-type Channels
N-type Channels
Sodium Channels
Overview
Channel Subtype Selectivity
Potassium Channels
Overview
Kv1.3
Kv1.5
Ca-activated channels
K(ATP)
KCNQ
Genetic and Acquired Channelopathies
Overview
HERG
Long QT Syndrome
Safety Issues in Ion Channel Drug Development
Angewandte Chemie
David Rampe is currently head of the Safety Pharmacology Department at Sanofi-Aventis Pharmaceuticals in Bridgewater, NJ, USA. Over the past 17 years he has worked in both the discovery and development areas of the pharmaceutical industry.
Wei Zheng is a Group Leader at the NIH Chemical Genomics Center. He was previously a Group Leader at Merck's centralized screening center. Over the past 12 years he has being working in the area of assay development and high throughput screening.
Murali Gopalakrishnan is a Project Leader in the Neuroscience Research Division of Abbott Laboratories, Illinois, USA. Over the past 12 years he has been engaged in various drug discovery programs in the areas of central nervous system, urology and pain.